Cullinan Therapeutics, Inc. announced that David Meek has been appointed to the Board of Directors, effective May 15, 2024. Mr. Meek most recently served as CEO and board member of Mirati Therapeutics, Inc, and previously as CEO and board member of FerGene, Inc. and Ipsen. Thomas Ebeling will resign from Cullinan?s Board of Directors at the end of his term on June 26, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.5 USD | +3.12% | -2.61% | +130.62% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+130.62% | 1.35B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Therapeutics, Inc. Announces Board Changes